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Replication-competent molecular clones of feline immunodeficiency virus (FIV) were isolated directly from
the DNA of bone marrow cells of a naturally FIV-infected cat. After transfection in a feline kidney cell line
(CrFK) and subsequent cocultivation with peripheral blood mononuclear cells (PBMC), the viral progeny of
the clones was infectious for PBMC but not for CrFK cells. PBMC infected with these clones showed syncytium
formation, a decrease in cell viability, and gradual loss of CD4+ cells. The restriction maps of these clones
differed from those obtained for previously described molecular clones of FIV derived from cats in the United
States. The predicted amino acid sequence similarity of the envelope genes of the two clones was 99.3%,
whereas the similarities of the sequences of the clones to those of two molecular clones from the United States,
Petaluma and PPR, were 86 and 88%, respectively. Most of the differences between the amino acid sequences
of the two clones and those of the clones from the United States were found in five different hypervariable (HV)
regions, HV-1 through HV-5. The viral progeny of one of these clones was inoculated into two specific-
pathogen-free cats. The animals seroconverted, and the virus could be reisolated from their PBMC.
Feline immunodeficiency virus (FIV) is a T-lymphotropic
lentivirus initially isolated from an immunodeficient cat (23).
FIV infection in cats can lead to immunological abnormali-
ties similar to those seen in human immunodeficiency virus
type 1 (HIV-1) infected humans, like a depletion of CD4+
cells in circulation (2, 3, 31). Similarly, the peripheral blood
mononuclear cells (PBMC) from FIV-infected cats show
reduced proliferative responses to mitogens and to exoge-
nous interleukin 2 (IL-2) in vitro (3, 13, 28). These similar-
ities in biological behavior between HIV-1 and FIV may
make FIV infection of cats a suitable small-animal system to
study lentivirus pathogenesis as a model for human AIDS
and may likewise identify the FIV system as a model for
HIV vaccine development.
Lentiviruses display a large degree of molecular and
biological variation. This variation is generally ascribed to
the low fidelity of the viral enzyme reverse transcriptase
(RT) in copying the viral genomic RNA to DNA (25, 26). The
use of complete molecular clones allows one to obtain
genomically homogeneous viral populations. Relating the
biological properties of such populations to the genomic
structure of the molecular clone from which they were
derived may reveal the molecular basis of biological varia-
tion and may identify determinants of viral virulence. To
date, molecular clones of three FIV strains have been
described, two from the United States (the 34TF10 clone of
the Petaluma strain [22, 30] and the PPR clone of the San
Diego strain [24] and one from Japan (JM1 [21]), which were
all obtained from the DNA of in vitro-propagated cells.
Culturing in vitro may select for certain virus subpopulations
and can induce new features in the propagated virus. Cul-
turing of simian immunodeficiency virus (SIV) in human
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cells, e.g., can lead to the introduction of a premature
termination codon in the viral transmembrane glycoprotein
(14, 17). These problems make the availability of complete
molecular clones obtained directly from the DNA of in
vivo-infected cells highly desirable. Here we report on two
replication-competent molecular clones derived directly
from the DNA of bone marrow cells from an FIV-infected
cat. The genomic structures of these clones and their pre-
sumed envelope gene sequences are presented.
HIV-1, HIV-2, and SIV infect cells via the CD4 molecule,
which acts as the cellular receptor for these viruses (8, 15,
18, 19). These viruses are also cytopathic for CD4+ cells in
vitro, and this cytopathic effect may at least in part underlie
the virally induced immunodeficiency characterized by
CD4+ cell depletion in vivo. The CD4 analog in cats has
been identified recently (1), but its role in FIV binding and
entry is not yet clear. FIV infection also results in a
reduction of CD4+ cells in circulation in infected cats. We
have therefore investigated whether the molecular clones of
FIV described here are cytopathic for CD4+ cells in vitro.
MATERIALS AND METHODS
Cells and virus. Bone marrow cells were obtained from the
femur of a 4-year-old naturally FIV-infected free-roaming
cat (Amsterdam-19) suffering from a generally debilitating
disease and intermittent disease symptoms, including respi-
ratory infections and chronic diarrhea, all suggestive of an
immunodeficiency syndrome (23, 32). The cells were washed
twice and used for isolation of genomic DNA (see below).
PBMC were isolated from heparinized blood from the cat
by Ficoll density gradient centrifugation. The PBMC were
washed three times with RPMI 1640 (GIBCO), supple-
mented with penicillin (100 IU/ml), streptomycin (100 jig/
ml), L-glutamine (2 mM), and P-mercaptoethanol (2 x 10-5
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M), designated culture medium (CM). A total of 107 PBMC
were stimulated with 5 jig of concanavalin A (ConA) (Flow
Laboratories, Inc.) per ml in CM supplemented with 10%
heat-inactivated fetal calf serum (FCS). After 3 days, the
cells were washed once and further cultured with CM
supplemented with 10% FCS and IL-2 (100 IU/ml) (Cetus).
The culture supernatant was monitored weekly for the
presence of FIV antigen in an FIV antigen capture enzyme-
linked immunosorbent assay (ELISA) as described previ-
ously (29). A virus stock of FIV from cat Amsterdam-19
(designated FIV Amsterdam-19) was made from the super-
natant of this culture 21 days after stimulation and stored in
aliquots at -135°C. The RT activity was assayed and was 7.0
x 10' cpm/ml.
PBMC were derived from heparinized blood of a specific-
pathogen-free (SPF) cat by Ficoll density gradient centrifu-
gation. The cells were washed twice and frozen at -135°C in
aliquots in CM supplemented with 10% FCS and 10%
dimethyl sulfoxide. Before use, the cells were thawed and
stimulated with ConA (5 ,ug/ml) for 3 days and further
cultured with IL-2 (100 IU/ml).
An FIV-susceptible clone of the Crandell feline kidney cell
line (CrFK) was obtained from N. Pedersen (32). The cells
were cultured in Dulbecco's modified Eagle's medium sup-
plemented with penicillin (100 IU/ml), streptomycin (100
ig/lml), L-glutamine (2 mM), P-mercaptoethanol (2 x 10-5
M), and 10% FCS.
DNA isolation. Genomic DNA was isolated from bone
marrow cells. A total of 108 bone marrow cells of cat
Amsterdam-19 were washed twice and lysed with 100 ,ig of
proteinase K per ml and 0.5% sodium dodecyl sulfate (SDS)
for 16 h at 42°C. Cesium chloride (1.25 g/ml of lysate) was
added, and after centrifugation for 44 h at 60,000 rpm in a 70
Ti rotor (Beckman), fractions containing the high-molecular-
weight DNA were collected, pooled, and dialyzed against
TE (10 mM Tris, pH 8.0, and 0.1 mM EDTA).
Southern blot analysis of genomic DNA. Genomic DNA
was digested with BamHI or NheI. After electrophoresis,
the DNA was transferred to nitrocellulose and hybridized
with the 32P-labeled gag probe P2 (see below) in hybridiza-
tion buffer (3x SSC [lx SSC is 0.15 M NaCl plus 0.015 M
sodium citrate], 50 mM Tris, 5x Denhardt's solution, 0.5%
SDS, 5 mM EDTA, 50% formamide, 10% dextran sulfate,
and 10 ,ug of salmon sperm DNA per ml). The blots were
washed twice with 0.2x SSC-0.1% SDS for 30 min at 68°C
each time and autoradiographed.
Molecular cloning of FIV proviral DNA. Genomic DNA
from bone marrow cells from cat Amsterdam-19 was par-
tially digested with Sau3A. After size fractionation on a 5 to
25% NaCl gradient, 10- to 20-kb fragments were ligated to
EMBL-3 lambda arms (Stratagene) and packaged in vitro.
The unamplified lambda phage library was screened with the
probes P2 (1.8-kb SstI-BamHI gag fragment) and P22 (2.1-kb
BamHI-BamHI pol fragment), which were obtained from R.
Olmsted (22), and ENV-4 (a 2.6-kb fragment spanning the
complete envelope gene obtained by polymerase chain reac-
tion [25a]).
Positive plaques were purified, and the DNA was isolated.
SphI-Sall fragments of these clones were subcloned in
pUC19. The subclones were used for the dideoxynucleotide
chain termination sequence reaction (27) of the env gene.
The nucleotide and protein alignments as well as the per-
centages of similarity were determined with Lasergene soft-
ware (DNAstar Inc., London, United Kingdom).
Purified lambda DNA was used for the construction of a
restriction enzyme map. Lambda DNA from the clones was
digested with the restriction enzymes BamHI, BglII, EcoRI,
KpnI, NheI, SphI, and SstI and, after electrophoresis on a
0.8% agarose gel, transferred to nitrocellulose. The filters
were subsequently hybridized with P2, P22, or ENV-4 and
autoradiographed.
DNA transfection. A sample of 5 jig of lambda DNA was
transfected into CrFK cells by using the cationic lipid
DOTMA (lipofectin; Bethesda Research Laboratories, Inc.)
according to the protocol of the manufacturer. Briefly, 5 jig
of DNA in 50 jil of H20 was mixed with 50 jil of lipofectin
and incubated for 15 min at room temperature. CrFK cells
were washed with serum-free Dulbecco's modified Eagle's
medium, and the lipofectin reagent-DNA complex was
added. Twenty-four hours after transfection, CM containing
20% FCS, 100 IU of IL-2 per ml, and 5 x 106 ConA- and
IL-2-stimulated PBMC from an SPF cat were added. After
72 h, the PBMC and CrFK cells were washed and cultured
separately. The culture supernatant was monitored for the
presence of FIV antigen in an FIV antigen capture ELISA.
Eighteen days after transfection, a virus stock was made and
stored in aliquots at -135°C. The RT activity was deter-
mined. The infected cells were used for electron microscopy
essentially as described by Gelderblom et al. (11).
Infection of PBMC. ConA- and IL-2-stimulated PBMC of
an SPF cat were infected with the molecular clones or with
the biological isolate FIV Amsterdam-19 by resuspending
107 PBMC in 1 ml of virus dilution in CM containing 2 x 104
cpm of RT activity per ml. After 1 h at 37°C, the cells were
washed twice with CM and cultured in CM supplemented
with 10% FCS and 100 IU of IL-2 per ml. Twice a week, 1.5
ml of culture supernatant was centrifuged (10 min at 300 x g)
and stored at -135°C until testing for the presence of FIV
antigen and RT activity. The cells were monitored for
cytopathic effects like syncytium formation and cell viability
and for the percentages of CD4+ and CD8+ cells by fluores-
cence-activated cell sorter analysis with monoclonal anti-
bodies provided by M. Cooper (1, 16).
RT assay. RT activity was assayed in a microassay as
previously described by Gregersen et al. (12), with minor
variations. Briefly, 1 ml of culture supernatant was precip-
itated with 0.25 ml of 32% polyethyleneglycol 6000-1.5 M
NaCl. The pellets were resuspended in 10 jil of lysis buffer
(50 mM Tris [pH 8.3], 20 mM dithiothreitol, 0.25% Triton
X-100) and mixed with 40 jil of H20 and 50 jil ofRT cocktail
(100 mM Tris [pH 7.9], 150 mM KCl, 10 mM MgCl2, 4 mM
dithiothreitol, 0.6 U of poly(rA) oligo(dT), 60 jiCi of [3H]
TTP per ml). After incubation at 37°C for 1 h, the DNA was
precipitated with 20 jil of 120 mM Na4P207 1OH20 in 60%
trichloroacetic acid for 15 min at 4°C. The DNA was spotted
onto glass fiber filters with a Skatron cell harvester and
washed with 12 mM PPNa in 5% trichloroacetic acid. The
filters were dried, and [3H]TTP incorporation was measured
in a ,-scintillation counter.
Nucleotide sequence accession number. The sequences re-
ported in this paper have been deposited in the GenBank
data base (accession no. for clone 19kl is M73964 and for
clone 19k32 is M73965).
RESULTS
Molecular cloning and characterization of FIV provirus.
Genomic DNA from bone marrow cells of a naturally
FIV-infected free-roaming cat (Amsterdam-19) was digested
with restriction enzymes and blotted onto nitrocellulose for
hybridization with probe P2, FIV-specific DNA could be
detected in this DNA preparation as well as in the DNA
J. VIROL.
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FIG. 1. Restriction map of infectious molecular clones of FIV
strains Petaluma (34TF10), San Diego (PPR), and FIV Amster-
dam-19 (19kl and 19k32). Restriction enzyme maps of 34TF10 and
PPR are as predicted from their published nucleotide sequences (24,
30). Maps of 19kl and 19k32 were obtained by single and double
restriction enzyme digestion of lambda DNAs which contain the
full-length clones, followed by Southern blotting and hybridization
with the 32P-labeled FIV-specific probes P2, P22, or ENV-4. Restric-
tion enzyme cleaving sites: B, BamHI; Bg, BglII; Rl, EcoRI; K,
KpnI; N, Nhel; Sp, SphI; and S, SstI.
obtained from the spleen cells of cat Amsterdam-19 and the
spleen and bone marrow cells of another naturally FIV-
infected cat (data not shown). Digestion with BamHI or
NheI yielded internal FIV fragments with sizes of 3.8 and 3.2
kb, respectively. These fragments are also found in the maps
of lambda clones 19kl and 19k32 (see below).
Full-length proviral FIV clones were obtained from an
EMBL-3 lambda phage library made directly from the DNA
of the bone marrow cells of cat Amsterdam-19 by using the
P2. P22, and ENV-4 probes for screening. The hybridizing
clones were plaque purified and used for the isolation of
lambda DNA. The replication competence of the cloned FIV
provirus was assayed by transfection into CrFK cells (see
below). Three clones (19kl, 19k32, and 19k36) gave rise to
FIV antigen production upon transfection and were charac-
terized further. Restriction maps of these three clones
showed a high degree of similarity (Fig. 1). The maps of
clones 19kl and 19k36 were identical, whereas an additional
BglII site is present in the envelope gene of clone 19k32. This
additional BglII site was later confirmed by sequence anal-
ysis. When the predicted maps of the two U.S. clones (24,
30) were compared with that of clone 19kl, only 14 of 22
(34TF10 compared with 19kl, respectively) and 14 of 21
(PPR compared with 19kl, respectively) restriction sites
appeared to be conserved. Between 34TF10 and PPR, 12 of
21 restriction sites are conserved (Fig. 1). This indicates a
high degree of heterogeneity among these different FIV
strains.
We obtained the nucleotide sequences of the envelope
genes of the three clones of FIV Amsterdam-19. The nucle-
otide sequences of the envelope genes and the preliminary
restriction site analyses of the 5'- and 3'-flanking sequences
of clones 19kl and 19k36 showed no differences, which
suggests that these clones are fully identical. On the other
hand, we found that clones 19kl and 19k32 differed in the
length of their flanking sequences (data not shown), and only
the sequences of these clones were analyzed further. The
2,571 nucleotides of the envelope genes of these clones differ
in only nine positions. Because of the lack of direct amino
acid sequence data, it is as yet unclear where the exact
initiation codon of the envelope gene is located. We have
presumed the conserved ATG at position 6264 of clone
34TF10 of the Petaluma strain (30) to be the initiation codon
for the env gene, which then encodes an 857-amino-acid
glycoprotein with a potential cleavage site after 611 amino
acids, resulting in a 611-amino-acid surface glycoprotein and
a 246-amino-acid transmembrane glycoprotein. The pre-
dicted amino acid sequences of the envelope glycoproteins
of these clones were compared with those of the 34TF10
clone of the Petaluma strain and the PPR clone of the San
Diego strain (24, 30) (Fig. 2). The amino acid identity of the
envelope glycoproteins of clones 19kl and 19k32 is 99.3%.
The sequence identities of these two highly related clones
with the 34TF10 and PPR clone envelope sequences are 86
and 84%, respectively. We have aligned the four envelope
gene sequences (Fig. 2). Although amino acid variation is
found throughout the entire env gene, we observed the
presence of five hypervariable (HV) regions, designated
HV-1 through HV-5, as indicated in Fig. 2. These HV
regions concur in part with the variable regions described by
Phillips et al. (24). All four sequences are remarkably colin-
ear, with insertions and/or deletions found only in HV-5
(Fig. 2). Most of the potential N-linked glycosylation sites
are conserved between the envelope sequences of all four
clones (21 of 22); some variation of the cysteine residues is
observed within the first 150 amino acids.
Biological characterization. Lambda phage, containing ap-
parently full-length proviral DNA of clones 19kl, 19k32, and
19k36, was transfected into CrFK cells. These were then
cocultivated with PBMC for 72 h. Both cell populations were
then cultured separately. In the PBMC cultures infected with
clones 19kl and 19k32, FIV antigen could be detected within
8 days after transfection. FIV antigen was also detected in
the PBMC culture of clone 19k36 12 days after transfection.
Transmission electron microscopy pictures from all of these
cultures showed mature and immature virus particles and
particles budding from the cell membrane (data not shown).
FIV antigen could not be detected in the supernatant of the
CrFK cell cultures. The PBMC cultures were expanded, and
virus stocks were stored at -135°C. The RT activities of the
stocks were 2.3 x 104, 2.9 x 104, and 0.5 x 104 cpm/ml for
19kl, 19k32, and 19k36, respectively. On the basis of appar-
ent genetic identity of 19kl and 19k36 (see above), we have
concentrated on clones 19kl and 19k32 for further analysis.
ConA- and IL-2-stimulated PBMC (107) from an SPF cat
were infected with equal amounts of RT activity (2 x 104
cpm) of the viral progeny of clone 19kl or 19k32 or the
biological isolate FIV Amsterdam-19 obtained from in vitro-
propagated PBMC. The cultures were monitored for syncy-
tium formation, cell death, percent CD4+ and CD8+ cells,
FIV antigen production, and RT activity. The results are
shown in Fig. 3. Syncytium formation was seen 4 days
postinfection (p.i.) in the culture infected with 19kl and 6
days p.i. in the culture infected with 19k32 or the biological
isolate (Fig. 4). FIV antigen and RT activity could be
detected after 11 (19kl) and 14 (19k32 and FIV Amsterdam-
19) days in the FIV-infected cultures but not in the nonin-
fected control culture for 28 days p.i. (Fig. 3A and B).
The percent viable cells decreased from 95 to 55% during
28 days of culturing in the noninfected culture, whereas
there was a more rapid decrease of viable cells in the
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FIG. 2. Comparison of the predicted amino acid sequences of the envelope genes of molecular clones of the FIV strains Petaluma
(34TF10), San Diego (PPR), and FIV Amsterdam-19 (19kl and 19k32). HV regions (HV-1 through HV-5) are boxed. Solid lines, potential
conserved glycosylation sites; dashed lines, nonconserved sites; closed circles, conserved cysteine residues; open circles, nonconserved
residues. The presumed cleavage site between the surface glycoprotein (SU) and the transmembrane glycoprotein (TM) is also shown (see
text for details).
FIV-infected cultures (only 15% viable cells after 28 days)
(Fig. 3C), indicating cell death caused by FIV infection.
The percentages of the viable cells which were CD4+ and
CD8+ cells could be measured accurately only during 18
days of culture following infection because of the low
percent viable cells after this period. The percentages of
viable cells which were CD4+ and CD8+ cells were 44 and
35%, respectively, at the time of infection. After 18 days of
culture, these percentages in the noninfected culture were 36
and 38%, respectively. The mean percent CD4+cells in all of
the infected cultures decreased to 6% in 18 days p.i. The
mean percent CD8+ cells increased to 66% in this period
(data not shown), indicating a selective depletion of CD4+
cells in infected cultures (Fig. 3D).
Two SPF cats were infected with the viral progeny of
molecular clone 19kl, and two cats were infected with the
biological isolate FIV Amsterdam-19. FIV could be isolated
from these cats 2 weeks p.i., and seroconversion occurred 2
weeks later (data not shown). This demonstrates that these
viruses are infectious in vivo.
DISCUSSION
We have generated molecular clones of FIV directly from
the DNA of bone marrow cells of an FIV-infected cat and
characterized these clones for genetic and biological proper-
ties. Cloning directly from in vivo-infected cells obviates the
need for in vitro culturing of FIV in cell lines or in stimulated
PBMC. In vitro culture systems may select some viral
genotypes over others, as has been shown in numerous
instances for HIV-1 (7, 9, 20), or may even introduce
modifications in the cultured virus as demonstrated for
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FIG. 3. Virus production, cell viability, and percent CD4+ cells in feline PBMC infected in vitro with FIV as described in the text. (A) RT
activities in culture supernatant; (B) FIV antigen in culture supernatant; (C) percent viable cells; (D) percentages of viable cells which were
CD4+. Symbols: -* , noninfected; O, biological isolate FIV Amsterdam-19; . molecular clone 19kl; +, molecular clone 19k32.
SIVmac (14, 17). These drawbacks bring the inherent danger
that a molecularly cloned virus obtained from in vitro
cultures is not representative of the virus population present
in the infected animal. The high load of FIV proviral DNA in
the bone marrow cells of the naturally infected symptomatic
cat Amsterdam-19 has allowed us to obtain complete molec-
ular clones of FIV directly ex vivo. FIV-specific DNA could
be detected in genomic DNA of bone marrow cells of cat
Amsterdam-19 and in the DNA of bone marrow cells of only
one of six other naturally infected cats. It is as yet unclear
whether the detection of FIV proviral DNA in the genomic
DNA of bone marrow cells of FIV-infected cats is a general
feature. In this paper, we show that the viral progeny of
these clones has biological properties very similar to the
virus isolate obtained from the PBMC of cat Amsterdam-19.
FIV has been shown to cause a depletion of CD4-bearing
cells in infected animals, as HIV-1 does in infected humans
(2, 3, 31). For HIV-1, this depletion may be partly explained
by its selective tropism for and cytopathic effect on CD4+
cells, which has been demonstrated in vivo. Additionally,
HIV-1 can downregulate the CD4 receptor on infected cells
(5, 6). Although the CD4 analog in cats has been identified,
the results as to its functioning as the receptor for FIV have
so far been inconclusive. We demonstrate here that an FIV
isolate as well as two infectious molecular clones of FIV
selectively deplete CD4+ cells from a culture of feline PBMC
(Fig. 3D). The viruses alsy induce the formation of syncytia
in these cultures, indicating that the observed CD4+ cell
depletion could well be the result of direct cytopathic effects,
although we cannot rule out that downregulation of CD4 also
plays a role. The fact that these molecularly cloned viruses
induce syncytium formation and deplete CD4+ cells in vitro
may indicate that they do the same in vivo upon experimen-
tal infection. Such effects would result in a progression
towards immunodeficiency. In preliminary experiments, the
viral progeny of at least one of the two described clones
(namely, 19kl) proved to be infectious in vivo. The experi-
mentally infected animals will be monitored closely for
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FIG. 4. Syncytium formation of feline PBMC which are infected with viral progeny of molecular clone 19kl (magnification, X400).
hematologic and immunologic parameters as well as for signs
of FIV disease.
To facilitate transfection of the molecular clones, we have
relied on an adherent cell line that is permissive for FIV
replication, namely, the CrFK T-cell line. After transfection,
the CrFK cells produced FIV particles whose viral progeny
was thereupon rescued by cocultivation with feline PBMC.
Interestingly, we could not show productive reinfection of
CrFK cells by these viruses, indicating that one round of
replication is not sufficient for the adaptation of FIV to CrFK
cells. At the same time, these data demonstrate that the lack
of growth of many FIV strains on CrFK cells is the result of
a block at viral entry rather than at virus replication.
To date, two envelope sequences of FIV molecular clones
have been obtained. The comparison of the sequences of
these two U.S. isolates revealed an amino acid sequence
similarity of approximately 85%. To assess the amount of
variation between strains from widely different geographical
locations, we have obtained the complete envelope se-
quences of the molecular clones 19kl and 19k32. These two
sequences are remarkably similar (99.3% similarity),
whereas they differ by approximately 15% from both U.S.
isolates, which is the amount of variation found between the
U.S. isolates. A high degree of sequence similarity between
two different proviruses is unusual for lentiviruses, which in
general show much more sequence variation, especially in
the envelope gene. The observed conservation may indicate
that the obtained FIV clones are the progeny of the original
viral clone that colonized the bone marrow of cat Amster-
dam-19.
To predict the amino acid sequence of the envelope gene,
we took the ATG at position 6264 of the 34TF10 clone of the
Petaluma strain to be the start codon for env. This results in
an 857-amino-acid glycoprotein with a potential cleavage site
at position 611 (30). The precursor of the 857 amino acids can
be cleaved into two smaller glycoproteins: an outer mem-
brane protein of 611 amino acids and a transmembrane
protein of 246 amino acids. The newly generated N terminus
at the presumed transmembrane glycoprotein is highly hy-
drophobic and could serve as a fusion domain as demon-
strated for the homologous regions in SIVmaC and HIV-1 (4,
10). Although there is no obvious sequence similarity be-
tween this domain in FIV and those of SIV and HIV-1, we
observed a high incidence of amino acids with very short
side chains like glycine and alanine in all three viruses. This
GA repeat may well be important for the function of the
fusion domain. Most of the structurally important features of
the envelope glycoproteins, like cysteine residues and
N-linked glycosylation sites, are conserved between these
clones. Some nonconserved cysteine residues were found in
the putative L gene region of the envelope glycoprotein,
preceding the leader sequence identified by others (24, 30).
The molecular clones described in this report have been
shown to be infectious both in vitro and in vivo. Such clones
may enable us to delineate the molecular basis of the
pathogenesis of FIV.
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